Over the past years, we have built SSI Diagnostica Group into a global company with a leading portfolio in infectious disease diagnostics, bringing together five companies: SSI Diagnostica, CTK Biotech, Beijing Genesee Biotech, TECHLAB, and, most
recently, Gulf Coast Scientific.

Operating as one company today, we supply more than 60 million diagnostic tests annually to customers in over 130 countries, with manufacturing and offices across Europe, the United States of America, and Asia. Our purpose is clear: to enable better treatment outcomes for patients by providing healthcare professionals with reliable tools to prevent, monitor, and diagnose infectious diseases.

Throughout the development of the Group, a guiding priority has been integration without dilution. We do not acquire companies to replace what they have built, but to strengthen and amplify it. This means aligning people, processes, and ways of working across geographies while preserving the scientific expertise, product quality, and customer relationships that define us.

This long-term perspective also shapes our approach to sustainability. In 2025, we established our first group-wide sustainability strategy, focusing on the areas where we have the greatest impact.

This first sustainability report marks an important milestone for us as an integrated company. It reflects where we stand today and sets the direction for the work ahead. We thank our colleagues for their contributions, and our customers and partners for their continued trust, as we work to bring lasting value to patients world wide.